Gonadotropin-releasing Hormone Antagonists Market

Gonadotropin-releasing hormone antagonists are used to treat advanced prostate cancer. They are also used to treat certain gynecologic conditions and are being studied in the treatment of hormone-sensitive breast cancer. Also called GnRH antagonist, LHRH antagonist, and luteinizing hormone-releasing hormone antagonist.

Gonadotropin-releasing Hormone Antagonists Market contains market size and forecasts of Gonadotropin-releasing Hormone Antagonists in global, including the following market information:

Global Gonadotropin-releasing Hormone Antagonists Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global Gonadotropin-releasing Hormone Antagonists Market Sales, 2017-2022, 2023-2028, (K Units)

Global top five Gonadotropin-releasing Hormone Antagonists companies in 2021 (%)

The global Gonadotropin-releasing Hormone Antagonists market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Peptides Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Gonadotropin-releasing Hormone Antagonists include AbbVie, Takeda, Astellas, Kissei, Veru Inc, Myovant Sciences, AstraZeneca, Ferring Pharmaceuticals and Jiangsu Hengrui Medicine Co. etc. In 2021, the global top five players have a share approximately % in terms of revenue.

surveyed the Gonadotropin-releasing Hormone Antagonists manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Gonadotropin-releasing Hormone Antagonists Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Units)

Global Gonadotropin-releasing Hormone Antagonists Market Segment Percentages, by Type, 2021 (%)

Peptides

Small Molecules

Global Gonadotropin-releasing Hormone Antagonists Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Units)

Global Gonadotropin-releasing Hormone Antagonists Market Segment Percentages, by Application, 2021 (%)

Prostate Cancer

Endometriosis

Uterine Fibroids

Female Infertility

Others

Global Gonadotropin-releasing Hormone Antagonists Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Units)

Global Gonadotropin-releasing Hormone Antagonists Market Segment Percentages, By Region and Country, 2021 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Gonadotropin-releasing Hormone Antagonists revenues in global market, 2017-2022 (Estimated), ($ millions)

Key companies Gonadotropin-releasing Hormone Antagonists revenues share in global market, 2021 (%)

Key companies Gonadotropin-releasing Hormone Antagonists sales in global market, 2017-2022 (Estimated), (K Units)

Key companies Gonadotropin-releasing Hormone Antagonists sales share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

AbbVie

Takeda

Astellas

Kissei

Veru Inc

Myovant Sciences

AstraZeneca

Ferring Pharmaceuticals

Jiangsu Hengrui Medicine Co